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Abstract
 
The nature and frequency of human histocompatibility leukocyte antigen (HLA) class I loss
mechanisms in primary cancers are largely unknown. We used flow cytometry and molecular
analyses to concurrently assess allele-specific HLA phenotypes and genotypes in subpopulations
from 30 freshly isolated cervical tumor cell suspensions.
Tumor-associated HLA class I alterations were present in 90% of the lesions tested, compris-
ing four altered pheno/genotype categories: (a) HLA-A or -B allelic loss (17%), mostly associ-
ated with gene mutations; (b) HLA haplotype loss, associated with loss of heterozygosity at 6p
(50%). This category included cases with additional loss of a (third) HLA-A or -B allele due to
mutation, as well as one case with an HLA class I–negative tumor cell subpopulation, caused by
a 
 
b
 
2-microglobulin gene mutation; (c) Total HLA class I antigen loss and retention of het-
erozygosity (ROH) at 6p (10%); and (d) B locus or HLA-A/B downregulation associated with
ROH and/or allelic imbalance at 6p (10%). Normal HLA phenotypes and ROH at 6p were
observed in 10% of the cases. One case could not be classified (3%).
Altered HLA class I antigen expression occurs in most cervical cancers, is diverse, and is
mainly caused by genetic changes. Combined with widespread tumor heterogeneity, these
changes have profound implications for natural immunity and T cell–based immunotherapy in
cervical cancer.
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Introduction
 
Cancer usually develops by a multistep process, character-
ized by the accumulation of genetic events within the tu-
mor cell (1). These may be associated with the activation of
genes not normally expressed in somatic cells, or mutations
within expressed genes. Virally induced tumors are also
marked by the expression of viral genes. The resulting ge-
notypic and phenotypic changes may provide the tumor
with a selective growth advantage. The ability of T lym-
phocytes to recognize peptide epitopes derived from cyto-
plasmic, nuclear, and/or viral proteins, presented in the
context of HLA class I molecules, potentially allows the
immune system to respond to these changes in the trans-
formed cell. This places HLA class I molecules at the center
of the immune response to tumors. However, at the same
time tumor cells may gain the ability to evade immune re-
sponses by downregulation or loss of expression of HLA
class I molecules.
Abnormal HLA class I antigen expression has been ob-
served at high frequencies in many different tumor types,
including melanoma, colon, cervix, breast, lung, and laryn-
geal cancers, and may range from loss of a single HLA class
I allele to complete loss of HLA class I antigen expression
(2). To understand the exact nature and impact of HLA
class I antigen loss in the course of carcinogenesis, it is cru-
cial to elucidate the underlying mechanisms and their rela-
tive frequency in any particular tumor system. The identifi-
cation of specific altered HLA class I phenotypes will be the
first step to further analyze the mechanisms responsible for
these HLA changes. In previous studies on the prevalence
and/or mechanisms of HLA class I antigen loss in tumors,
at least three major restrictions apply. First, the prevalence
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of altered class I phenotypes in various primary cancers has
been studied by immunohistochemistry on tissue sections
(2, 3). However, the panels of anti–HLA class I antigen an-
tibodies (mAbs) used in such studies did not cover all the
HLA-A and -B alleles represented in the patient population
(3–6). Therefore, the incidence and interpretation of HLA
“loss phenotypes” may be underrated. Second, criteria for
interpretation and classification of staining results are not yet
uniformly established (7), especially with respect to pheno-
typic intratumor heterogeneity. Finally, the mechanisms un-
derlying HLA class I antigen loss have been studied mostly in
cultured tumor cell lines in which molecular genetic analy-
ses are easier to accomplish (2, 8–18). Only few such stud-
ies have confirmed results in the corresponding primary tu-
mors (11, 19, 20). To avoid detection of defects possibly
acquired in vitro, mechanistic studies should be extended
to fresh primary tumor material.
Because integral analyses of complete HLA I class loss
phenotypes and their underlying mechanisms in any one
tumor system are still incomplete, the relative prevalence of
specific HLA class I antigen loss mechanisms in any partic-
ular tumor system remains to be established.
In cervical cancer, a minimum estimate of HLA class I
antigen loss in primary cervical cancers has previously been
made at 73% (4), while the underlying mechanisms are poorly
understood. The clinical impact of HLA class I downregu-
lation in cervical cancer has been increasingly documented,
while immunotherapeutic efforts against human papilloma-
virus (HPV)
 
1
 
-infected cervical cancer cells are made at the
same time (21–24). Therefore, it is mandatory to assess the
exact nature and distribution of altered phenotypes in pri-
mary cervical cancer tissues. We have recently demonstrated
various molecular mechanisms of HLA class I antigen loss
in cervical cancer cell lines and their corresponding primary
tumors (19, 20). These ranged from regulatory to structural
genetic defects, including genomic deletions and mutations
in class I genes. One of the latter defects, loss of heterozy-
gosity (LOH) at chromosome 6p, containing the HLA genes
at 6p21.3, was shown to cause loss of a complete HLA class
I haplotype. LOH at 6p has been independently identified
in primary cervical cancers at high frequencies, varying
from 40 to 70%, without knowledge of HLA class I antigen
expression in these tumors (25–29).
In this study, we have applied a methodology for the in-
tegral analysis of HLA class I antigen loss in the cervical
cancer model, based on detection of all HLA-A and -B al-
leles by use of an extensive allele-specific anti-HLA mAb
panel and multiparameter DNA flow cytometry on pri-
mary cervical cancer cell suspensions. Molecular analyses
were performed on flow-sorted phenotypically distinct tu-
mor populations from the fresh tumor samples. We deter-
mined the prevalence of particular altered HLA class I phe-
notypes and the related “6p microsatellite (MS) genotypes,”
with a focus on 6p21.3. In addition, we screened for allele-
specific mutations and 
 
b
 
2-microglobulin (
 
b
 
2m) mutations
in tumors with allelic losses or cases with total HLA class I
antigen loss, respectively. We demonstrate a successful ap-
proach to the integral analysis of HLA class I pheno- and
genotype alterations in primary cervical tumors. Most im-
portantly, we report that the majority of the observed HLA
class I phenotype changes in cervical cancer cells are caused
by genetic alterations at chromosome 6p21.3.
 
Materials and Methods
 
Primary Tumor Cell Suspensions
 
Consecutive cases of cervical cancer tissues were obtained with
informed consent from patients who were operated on according
to the Wertheim hysterectomy protocol at the Department of Gyne-
cology of the Leiden University Medical Center. Immediately af-
ter surgery, tissue for diagnostic purposes was fixed in formalin, a
piece of the tumor tissue was snap-frozen in liquid isopentane and
stored at 
 
2
 
70°C, and the remaining part, ranging in weight from
0.2 to 3.0 g, was cut into 1-mm
 
3
 
 pieces and washed. Tumors
were classified as squamous (
 
n
 
 5 
 
21), adeno (
 
n
 
 5 
 
8), or adeno-
squamous (
 
n
 
 5 
 
1) carcinoma based on routine pathohistological
examination. Each tumor was analyzed for the presence of type-
specific HPV DNA by PCR and sequencing, as described previ-
ously (30). Of the 30 tumors, 18 (60%) contained HPV16 (
 
n
 
 5
 
11) or HPV18 (
 
n
 
 5 
 
7), 2 tumors contained HPV45 (7%), and
HPV56, 59, 70, 73, and 58
 
1
 
67 were each found once (20%). In
five tumors, no HPV was detected.
The minced tumor fragments were enzymatically digested in
5 ml/g tissue of FCS-free DMEM (GIBCO BRL) medium con-
taining 0.002% DNase and 4 mg/ml collagenase type IA, or me-
dium containing 0.002% DNase, 0.5 mg/ml collagenase type II,
and 0.25% trypsin (enzymes obtained from Sigma Chemical Co.)
at 37°C for 1–2 h. After washing, cell pellets were extensively pi-
petted using a 25-ml plastic pipette to shear cells from remaining
cell lumps. Suspensions were then sieved over a 100-
 
m
 
M nylon
filter (Verseidag-Industrietextilien GmbH) and the enzymatic ac-
tivity was blocked by addition of FCS to a 10% concentration.
After washing in FCS-containing medium on ice, the yield and
viability of the resulting single cell suspension were determined
using the trypan blue exclusion method. Average yields were 5 
 
3
 
10
 
6
 
 cells/g tissue. The average viability was 
 
.
 
80%. Single cell
suspensions were frozen in 90% FCS/10% DMSO in liquid ni-
trogen until further use.
 
Patient PBL/HLA Typing
 
Heparin blood was separately obtained from each patient, and
PBLs were isolated using standard Ficoll gradient centrifugation.
HLA typing on PBLs was performed by the standard National In-
stitutes of Health microcytotoxicity technique at the Department
of Immunohematology and Bloodbank of the Leiden University
Medical Center.
 
Abs
 
Anti-HLA mAbs. 
 
To detect HLA class I monomorphic de-
terminants and relevant allele specificities in each suspension, a
suitable subpanel of anti-HLA mAbs, including negative isotype
control mAbs, was chosen from a large panel of murine and hu-
 
1
 
Abbreviations used in this paper:
 
 a.i., allelic imbalance; APC, allophycocy-
anin; 
 
b
 
2m, 
 
b
 
2-microglobulin; HPV, human papillomavirus; LCA, leu-
kocyte common antigen; LOH, loss of heterozygosity; MS, microsatel-
lite; MSI, MS instability; PI, propidium iodide; ROH, retention of
heterozygosity. 
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man anti-HLA mAbs, described in a previous study (19). Human
anti-HLA mAbs (hu-mAbs) were used in flow cytometric analy-
ses of cell suspensions and not on tissue sections, due to cross-
reactivity with human immunoglobulins present in such tissues.
Murine anti-HLA mAbs (mu-mAbs) were applied both in flow
cytometry and immunohistochemistry. To account for differences
in mAb specificities and/or affinities, several mAbs were used to
address the same HLA alleles. Murine and human anti-HLA mAbs
were used at optimal titers as described previously (19).
 
Antitumor mAbs. 
 
A mixture of mAbs (all IgG1) designed to
detect all keratins known to be differentially expressed in cervical
cancers was used for staining the epithelial (tumor) cells in the
suspensions (31). This mixture contained culture supernatants
from clones 80, 6B10, M20, and M9 (Eurodiagnostica BV), and
the mAbs MNF116, DE-K10, OV-TL 12/30, BA17 (DAKO A/S),
KS-1A3 (Sigma Chemical Co.), and AE1/AE3 (Boehringer Di-
agnostica). All reagents were used at optimal dilutions established
in titration experiments.
 
Anti-“normal” mAbs. 
 
Clone 4B2 (IgG2a) was used to stain
surface CD45 (leukocyte common antigen [LCA]) on cells of the
leukocyte lineage. Clone V9 (IgG2b), directed against vimentin,
was used for intracellular staining of nonepithelial (nontumor) cells,
such as leukocytes or fibroblasts. Both mAbs were used at optimal
 
Table I.
 
Primers Used for PCR Amplification and Sequencing of HLA-A/HLA-B Exons 2–4 and 
 
b
 
2m Exons 1–2
 
PCR Primer Position (nt) Specificity Sequence
 
*
 
HLA
 
‡
 
Exon 2 Aex2F In1 (83–100) HLA-A (
 
6
 
B/C) 5
 
9
 
-gcg cck gga sga ggg tc-3
 
9
 
Bex2F In1 (39–56) HLA-B 5
 
9
 
-agg agm rag ggg acc gca-3
 
9
 
Aex2R In2 (37–59) HLA-A 5
 
9
 
-ccg tcc gtg ggg gat ga-3
 
9
 
Bex2R In2 (35–58) HLA-B excl B5801 5
 
9
 
-gtm cgt ggg gga tgg gga-3
 
9
 
Exon 3 A2
 
99
 
ex3F Ex2 (250–271) HLA-A2, 24, 34 5
 
9
 
-gga cgg gga gac acg gaa a-3
 
9
 
A3
 
99
 
ex3F Ex2 (250–271) HLA-A1, 3, 11 25, 26, 30 5
 
9
 
-gga cca gga gac acg gaa t-3
 
9
 
Aex3sR In3 (89–109) HLA-A 5
 
9
 
-ata ttc tag tgt tgg tcc caa-3
 
9
 
Bin1F
 
§
 
In1 (38–58) HLA-B 5
 
9
 
-gag gag mra ggg gac cgc ag-3
 
9
 
Bin3R
 
§
 
In3 (37–69) HLA-B 5
 
9
 
-gag scc atc ccc gsc gac cta t-3
 
9
 
Exon 4 Aex4pF In3 (575–597) HLA-A24 5
 
9
 
-gat ggc cac atg cat gct g-3
 
9
 
Aex4pF
 
99
 
In3 (575–597) HLA-A rest 5
 
9
 
-gat rgc cac atg ygt gct g-3
 
9
 
Bex4pF In3 (604–624) HLA-B excl B5401 5
 
9
 
-gts cca tga rag atg caa agc-3
 
9
 
Aex4pR Ex4 (873–891) HLA-A excl A8001 5
 
9
 
-ctc agg gtg agg ggc ttg-3
 
9
 
Bex4pR Ex4 (867–884) HLA-B (
 
6
 
C) 5
 
9
 
-tga ggg gct tcg gca gc-3
 
9
b
 
2m
Exon 1
 
b
 
2ex1F Ex1 (806–824)
 
b
 
2m 5
 
9
 
-ggc tgg gca cgc gtt taa t-3
 
9
b
 
2ex1R Ex1 (972–990)
 
b
 
2m 5
 
9
 
-agg gag aga agg acc aga g-3
 
9
 
Exon 2
 
b
 
2ex2F Ex2 (81–102)
 
b
 
2m 5
 
9
 
-tac cct ggc aat att aat gtg t-3
 
9
b
 
2ex2R Ex2 (430–451)
 
b
 
2m 5
 
9
 
-gac tac tca tac aca act ttc a-3
 
9
 
F, forward; R, reverse; nt, nucleotide position(s); 
 
6
 
, and some; k 
 
5
 
 g or t; m 
 
5
 
 c or a; r 
 
5
 
 a or g; s 
 
5
 
 c or g; w 
 
5
 
 a or t; y 
 
5
 
 c or t; In, intron; Ex, 
exon. HLA class I intron sequences were described by Cereb et al. (reference 58).
 
*
 
Sequencing primers used for each reaction are the same as listed, but shortened at the 5
 
9
 
 end for the sequence reaction at a melting temperature of
52–54
 
8
 
C, and labeled with Texas red. The Texas red–labeled sequencing primers used for sequencing of the HLA-B exon 3 product were described
previously (reference 20).
 
‡
 
HLA class I sequences were described by Mason and Parham (reference 59), and 
 
b
 
2m exon sequences were taken from GenBank (acc. nos.
M17986 and M17987).
 
§
 
The listed primers have a melting temperature of 58–60
 
8
 
C, except for the HLA-B exon 3 primers, with melting temperatures of 66
 
8
 
C and 70
 
8
 
C,
respectively.
dilutions established in separate titration experiments. All dilutions
were made in PBS, containing 1% BSA (Sigma Chemical Co.).
 
Immunohistochemistry
 
A standard three-step, indirect immunoperoxidase technique
was performed on fresh frozen tumor tissues, as described previ-
ously (19). For each tumor, consecutive sections were stained
with antikeratin mAbs, the anti-LCA mAb, the antivimentin
mAb, and a relevant panel of murine anti–HLA class I mAbs, re-
spectively. Loss of expression was defined by the inability to detect
an HLA allele on tumor cells with concurrent positive expression
on stromal cells and infiltrating immune cells.
 
Multiparameter DNA Flow Cytometry
 
A four-color, seven-step staining procedure for the simultaneous
flow cytometric detection of HLA class I alleles and DNA con-
tent on normal cells and tumor cells, CD45 on leukocytes, and
vimentin in nonepithelial cells was performed (31; Corver, W.E.,
L.A. Koopman, C.J. Cornelisse, and G.J. Fleuren, manuscript
submitted for publication). In brief, consecutive staining proce-
dures were as follows. 10
 
6
 
 cells per tube were incubated on ice for
30 min with 100 
 
m
 
l of the appropriate mouse or human allele-
specific anti-HLA mAb. In tubes containing hu-mAbs, anti- 
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CD45 IgG2a mAb was added in this first step. Cells were washed
with PBS/1% BSA (PBA). Cells were then incubated for 30 min
with 100 
 
m
 
l biotinylated goat Ig specifically directed against ei-
ther mouse or human Ig, together with a goat anti–mouse IgG2a-
FITC conjugate against the CD45 mAb (in the hu-mAb cases
only). These polyclonal secondary reagents (Southern Biotech-
nology Associates) were diluted 1:100. 100 
 
m
 
l 1:200 streptavidin-
allophycocyanin (APC; Molecular Probes) was added to all tubes
for 30 min. After washing in PBS, cells were fixed and permeabi-
lized using freshly prepared phosphate-buffered 1% paraformalde-
hyde (Merck) containing 160 
 
m
 
g/ml lysolecithin (Sigma Chemi-
cal Co.) for 5 min (31) then washed with PBA. All tubes, except
those containing mu-mAbs of the IgG1 isotype, were then incu-
bated with a mixture of murine antikeratin IgG1 mAbs for 30
min. In the tubes containing mu-mAbs (of any isotype), a directly
FITC-labeled antivimentin (IgG2b) mAb was added. After wash-
ing, goat F(ab
 
9
 
)
 
2
 
 anti–mouse IgG1-RPE polyclonal antibodies
(SBA), diluted 1:200, were added for 30 min to the keratin mix–
containing tubes. Cells were then washed, resuspended in 0.5 ml
DNA staining solution (0.1% RNase; Calbiochem) and 100 
 
m
 
M
propidium iodide (PI) in PBA, incubated for 30 min at 37°C, and
kept at 4°C until further analysis. The exclusions in the mouse
HLA mAb–containing tubes were introduced to avoid cross-
reactivity caused by similar mouse isotypes; the antivimentin (all
nonepithelial cells) IgG2b mAb is used to substitute for the com-
bined use of LCA ([nonepithelial] leukocyte) directed IgG2a
mAbs and antikeratin (epithelial) IgG1 mAbs. There is no antici-
pated cross-reactivity between IgG2a LCA– or IgG1 keratin–spe-
cific mouse mAbs and hu-mAbs.
 
Flow Cytometry. For each measurement, data from 10,000–
20,000 single cell events were collected using a standard FACS-
Calibur™ flow cytometer (Becton Dickinson Immunocytometry
Systems) as described previously (31). Data were analyzed using
WinList 3.0 and ModFit 5.2 software (Verity Software House).
Flow Sorting and DNA Isolation
Flow Sorting.  Flow sorting was performed using a FACStarPLUS™
flow cytometer (Becton Dickinson Immunocytometry Systems).
Tumor cells were sorted on keratin expression (RPE, FL2), while
mutually excluding LCA- or vimentin-positive (FITC, FL1) cells,
combined or not with a gate on DNA aneuploid cells activated in
the FL3 channel (PI, FL3) (Fig. 1). Conversely, normal cells were
sorted on LCA or vimentin expression while gating on keratin-
negative (diploid) cell populations. In the case of heterogeneous
(negative and positive) HLA class I antigen expression (APC,
FL4) within the tumor cell population, phenotypically distinct
subpopulations were sorted separately as well. Heterogeneity of
HLA class I antigen expression was never observed within the
normal (LCA1/Vim-positive/keratin-negative) cell population.
DNA Isolation.  Dependent on the amount of material avail-
able, flow-sorted tumor cells and normal cells were suspended at a
concentration of 500–10,000 cells/ml DNA isolation buffer (0.3
mg/ml proteinase K in 10 mM Tris-HCl pH 8.3, 0.5% Tween
20, 1 mM EDTA). From each patient, genomic DNA isolated from
PBLs was used as an external control. PBLs were suspended at a
concentration of 1,000–10,000 cells/ml in the same buffer. DNA
was extracted by digestion at 56°C overnight, followed by inacti-
vation at 100°C for 10 min, and stored at 4°C.
MS Analysis
The basic set of MS markers used comprised F13A1, D6S105,
D6S265, MICA, TNF-a, and D6S291, spanning the short arm of
chromosome 6, with emphasis on the HLA region at 6p21.3.
One or two additional markers (MogC, D6S510) were used in
cases with less than three informative markers or to clarify ambig-
uous patterns. All forward primers were 59 labeled with a fluoro-
chrome (Fluordite; Amersham Pharmacia Biotech) during syn-
thesis on a Millipore Expedite DNA Synthesizer. Primer sequences
and locations were available from the Genome Database (http://
www.gdb.org) and/or described by Foissac et al. (32, 33). PCR
amplification of genomic DNA, subsequent gel electrophoresis
on an Automated Laser Fluorescence DNA sequencer (ALF; Am-
ersham Pharmacia Biotech), and data acquisition and analysis (ALF
Manager software and Fragment Manager software; Amersham
Pharmacia Biotech) were performed, as described elsewhere (19).
Allele-specific PCRs
In some cases, additional HLA-Bw4/6 or allele-specific PCRs
were performed to assist assignment of the correct HLA class I
haplotype. For specific amplification of HLA-Bw4 and Bw6 se-
quences, the Bex2F forward primer (Table I) was used in combina-
tion with Bw4-specific (IHCW32: 59-cgc tct ggt tgt agt agc g-39)
or Bw6-specific (IHCW31: 59-cgc tct ggt tgt agt agc c-39) reverse
primers, both located in exon 2 at nucleotide position 319–336.
The amplified product sizes were 350 bp. For specific amplifica-
tion of HLA-A2, HLA-A11, or HLA-A24 sequences the HLA-A
exon 3 forward primers listed (Table I) were used in combination
with reverse primers A2/24R (59-gsa gga agc gcc mgt ccg a-39)
Figure 1. Examples of altered HLA-A/B phenotypes in cervical cancer cell suspensions, detected by flow cytometry. (A) HLA-B63 allele–specific
downregulation in tumor 14. I, Gates are set on the keratin-positive cells (R3, red) and on LCA-positive cells (R2, green). The diagonally shaped distri-
bution of keratin-positive, LCA-negative cells (R3) is caused by spectral cross-talk of the FL2 into the FL1 caused by the broad emission spectrum of the
DNA stain PI (references 56, 57). II, These cells coincide with the aneuploid and diploid cell populations, respectively. However, keratin-positive cells
also constitute a small peak in the diploid range (arrow). III and IV, HLA-A24 (mu-mAb A11.1M), HLA-A31 (hu-mAb OK4F9), HLA-B27 (hu-mAb
KG30A7), and HLA-B63 (hu-mAb OK3F10) are expressed on the LCA-positive diploid cells (gated on R2). Open histograms represent an irrelevant
HLA control (hu-mAb 44B8 against HLA-A10). V and VI, HLA-A24, -A31, and -B27 are expressed on the keratin-positive aneuploid cells (gated on
R3), but HLA-B63 is not. VII, The DNA versus HLA-B63 plot shows that keratin-positive diploid cells express HLA-B63, whereas the aneuploid cells
are negative compared with the irrelevant HLA control (VIII). (B) Complete loss of HLA-A26 (hu-mAb OK4F9) and HLA-B51 (mu-mAb 116.5.28) and
heterogeneous loss of HLA-A24 (mu-mAb A11.1M), HLA-B7 (mu-mAb 126.39), and total class I (mu-mAb W6/32) expression in tumor 49. I, As in A,
keratin-positive cells (red) and vimentin-positive cells (green) coincide with the aneuploid tumor and diploid control cell populations, respectively (II). All
HLA-A/-B alleles and total HLA class I antigens are expressed on control cells (III, IV, and VIII). On tumor cells, HLA-A26 and -B51 are not expressed,
as the peaks overlap the irrelevant HLA control mu-mAb GAPA3 against HLA-A3 (open histograms; black for control cells, red for tumor cells). HLA-
A24 and -B7 are partially lost, as shown by the bimodal distributions in V and VI. VII, with respect to total HLA class I, three distinct tumor cell popula-
tions emerge, expressing no, intermediate, and high levels of HLA class I antigens. (C) Loss of total HLA class I antigen expression in tumor 26. In analogy
to B, keratin-positive (red) and vimentin-positive (green) cells coincided with near-diploid tumor and diploid control cell populations, respectively (I).
Compared with an irrelevant HLA control (mu-mAb 126.39 against HLA-Bw6) in III, no HLA class I antigens are expressed on the near-diploid tumor
cell population (II). However, a small fraction of diploid keratin-positive cells is discernible that does react with the W6/32 mAb.966 The Genetic Basis of HLA Class I Loss in Cervical Cancer
or A3/11R (59-cca cgt cgc agc cat aca tt-39), both located in exon
3 at nucleotide positions 385–405 and 363–384, respectively. The
amplimer sizes were z375 (HLA-A2/24) and 360 bp (HLA-A3/11).
Amplification was performed in a total volume of 50 ml, con-
taining PCR buffer (50 mM KCl, 10 mM Tris-HCl [pH 8.4],
BSA [0.06 mg/ml], and 1.5 mM MgCl2), 6–60 ng of DNA, all
four deoxynucleoside triphosphates (each at 20 pmol as a mixture
from Amersham Pharmacia Biotech), 50 pmol of each primer,
0.5 U Ampli-Taq polymerase (Perkin-Elmer), and distilled sterile
H2O. The touchdown PCR profile consisted of a 5-min dena-
turation at 96°C; five cycles of 30 s at 96°C, 30 s at 65°C (minus
1°C per cycle), and 30 s at 72°C; 30 cycles of 30 s at 96°C, 30 s at
60°C, and 30 s at 72°C; and a final 5-min extension step at 72°C.
Detection of Mutations in HLA-A/B or b2m Genes
PCR Amplification.  Primers designed for separate amplifica-
tion of exons 2, 3, and 4 of the HLA-A and HLA-B genes and
exons 1 and 2 of the b2m gene are listed in Table I. All of these
primers were 59 labeled with Cy-5 and obtained from Isogen
Bioscience BV. Amplification was performed as described in the
previous section, except for slight modifications in the PCR used
for amplification of HLA-B exon 3, with a touchdown profile
from 70 to 65°C, 72°C elongation steps of 1 min, and final ex-
tension at 72°C for 10 min. The amplimer sizes were 420 bp
(HLA-A and -B exon 2), 700 bp (HLA-A exon 3), 930 bp
(HLA-B exon 2/3), 355 bp (HLA-A exon 4), 530 bp (HLA-B
exon 4), 185 bp (b2m exon 1), and 370 bp (b2m exon 2).
Sequencing.  Sequencing was performed as described previ-
ously (20) using the Thermo Sequenase core sequencing kit as
described by the manufacturer (Amersham Pharmacia Biotech).
Sequencing primers used are modified from the primers listed in
Table I (see legend). All primers were purchased from Isogen
Bioscience BV. In brief, 1 pmol of Texas red–labeled forward (F)
or reverse (R) oligonucleotide primer was used per PCR, consist-
ing of 25 cycles (95°C for 30 s, 60°C for 20 s, and 72°C for 20 s
each) on a PTC-200 Peltier Thermal Cycler (MJ Research).
Samples were directly subjected to electrophoresis on a Vistra
DNA sequencer 725 (Amersham Pharmacia Biotech) at 35 W for
12 h, and subsequently analyzed with the Assign v5.0 software
package (Amersham Pharmacia Biotech).
Results
Detection of Altered HLA-A and -B Phenotypes in Cervical 
Cancer Cell Suspensions
Flow Cytometry. 30 cervical tumor cell suspensions were
analyzed by multiparameter DNA flow cytometry to deter-
mine allele-specific HLA-A and -B expression. Allele-specific
HLA class I antigen expression of tumor cells was measured
in the keratin-positive fractions, and on normal cells in the
keratin-negative, LCA/vimentin-positive fractions (Fig. 1).
Tumor-associated HLA-A/B phenotype alterations were
initially identified in 26 (87%) of the 30 tumors (see Fig. 4).
Various altered HLA class I phenotypes emerged, which var-
ied from total or partial loss of a single HLA-A or -B allele
(Fig. 1 A), total or partial loss of two HLA-B alleles or an
HLA-A and -B allele (Fig. 2 A), and loss of three alleles (two
HLA-A and one HLA-B or vice versa, in three cases, to loss
of all four HLA-A/B alleles in six cases. The latter category
comprised three tumors with (partial) retention of W6/32 re-
activity (total HLA-A/B loss, Fig. 1 B) and three tumors that
completely lacked W6/32 mAb reactivity (total HLA class I
loss, Fig. 1 C). In four cases, the constitutive HLA-A/B phe-
notype was expressed on the tumor cells.
The examples shown in Fig. 1, A–C, and Fig. 2 A illus-
trate that the use of keratin mAbs is critical to the identifi-
cation of tumor cells within an overall DNA diploid cell
suspension (Fig. 2 A), whereas it clearly facilitates this
identification in DNA aneuploid or near-diploid tumors
(Fig. 1, A–C).
Flow Cytometry Versus Immunohistochemistry. To illustrate
the identification of tumor cells, stromal, and/or infiltrat-
ing immune cells within the original histological context,
as well as to independently analyze the expression of
HLA-A/B alleles and monomorphic HLA class I (W6/
32), frozen sections of each tumor were stained by immu-
nohistochemistry. Some allelic specificities could not be
detected by the anti-HLA–directed mu-mAbs used on tis-
sue sections. These could only be analyzed on the corre-
sponding suspension by flow cytometry using anti-HLA–
directed hu-mAbs. The example in Fig. 2 depicts a tumor
with loss of HLA-A2 and HLA-B51 expression in the tu-
mor cell fraction, as measured by flow cytometry (Fig. 2
A). Immunohistochemistry on consecutive frozen sections
of this tumor illustrates the same loss of HLA-A2 and
HLA-B51 expression within tumor cell areas as concomi-
tantly identified with antikeratin mAbs (Fig. 2 B). Positive
staining of these HLA antigens was observed on LCA-
positive stromal cells and tumor-infiltrating leukocytes.
This illustrates the advantage of flow cytometry and sort-
ing over microdissection of tumor cells from a frozen tu-
mor section in the presence of contaminating normal in-
filtrating leukocytes.
Since several alleles were undetected, resulting from the
lack of allele-specific mu-mAbs available for frozen sections,
the assignment of each of these tumors to a particular loss
phenotype category was not possible by immunohisto-
chemistry. Apart from these differences, immunohisto-
chemical and flow cytometric detection of allele-specific
HLA-A/B or total HLA class I antigen expression was in-
congruous in several cases. These discrepancies were mostly
such that while heterogeneous (positive and negative) ex-
pression was observed by flow cytometry, negative expres-
sion was seen by immunohistochemistry. In some other
cases, positive expression as detected by flow cytometry was
detected as heterogeneous or negative expression by immu-
nohistochemistry. Both observations underline the high sen-
sitivity of flow cytometry compared with immunohisto-
chemistry.
Altered HLA Class I Phenotypes in Relation to Chromosome 
6p MS Genotype 
To determine the status of heterozygosity at chromo-
some 6p, in particular in the HLA region at 6p21.3, MS
analysis was performed on DNA isolates from flow-sorted
HLA–phenotyped tumor cell subpopulations. Where pos-
sible, tumor cell fractions that displayed heterogeneous,
i.e., positive and negative, expression of HLA alleles were
separately sorted.967 Koopman et al.
An integral example of the analyses performed to deter-
mine HLA class I phenotype and 6p MS genotype is shown
in Fig. 2. Fig. 2 C shows a representative MS measure-
ment, performed on the cell fractions sorted from a tumor
cell suspension that displayed loss of HLA-A2 and HLA-
B51 expression (Fig. 2 A). The allelic ratio for MS marker
D6S265 in DNA from autologous PBLs was the same as
observed in DNA from the flow-sorted vimentin-positive
internal control cells. One of the D6S265 alleles was com-
pletely lost in DNA obtained from flow-sorted keratin-
positive tumor cells (Fig. 2 C), representing true loss of
heterozygosity (LOH), apparently involving both HLA-
A2 and -B51 loss.
Other examples illustrating allelic imbalance (a.i.), LOH,
and retention of heterozygosity (ROH) are shown in Fig.
3. For clarity, the chosen examples match the tumors de-
picted in Fig. 1, A–C. Fig. 3 A is representative for a.i.
observed in DNA from flow-sorted aneuploid tumor cells
that displayed loss of HLA-B15 expression (Fig. 1 A). Fig.
3 B represents the MS analysis for tumor 49 shown in Fig.
1 B, which displayed heterogeneous and complex loss of
all HLA-A and -B alleles and HLA class I antigen reactiv-
ity. All sorted tumor cell fractions of this tumor, including
separately sorted HLA-A24 and HLA-B7 positive and
negative cells and the overall keratin-positive (HLA-A26
and -B51 negative) cell population, show the same LOH.
This implies that not HLA-A24 and -B7, but rather HLA-
A26 and -B51, are involved in the observed LOH. Fig. 3 C
shows a representative MS measurement for the flow-
sorted fractions of tumor 26 with loss of total HLA class I
antigen expression, shown in Fig. 1 C. In the flow-sorted
tumor cell fraction, the same allelic ratio is found as in
control cells, demonstrating ROH.
The analyzed data for the complete panel of MS markers
used on DNA from each flow-sorted tumor cell fraction,
together with a description of the corresponding HLA-A/B
phenotype, are presented in Fig. 4. On the basis of these
combined results, four major altered pheno/genotype cate-
gories emerged. First, loss of a single HLA-A or -B allele
with variable patterns of allelic retention, imbalance, and
LOH at 6p was found in five tumors (17%; Fig. 4 A). An
example from this category is shown in Fig. 1 A and Fig. 3
Figure 2. Combined HLA-A/B
phenotype analysis by flow cytom-
etry and immunohistochemistry,
and MS analysis in one individual
cervical tumor (51). (A) Both ker-
atin-positive (red) and vimentin-
positive (green) cell populations (I)
are in the DNA diploid range (II).
III, All of the patient’s HLA-A and
-B alleles are expressed on the
internal vimentin-positive con-
trol cells, as detected by mu-
mAbs BB7.2 (HLA-A2), A11.1M
(HLA-A24), 116.5.28 (HLA-B51
[Bw4]), and 126.39 (HLA-B35
[Bw6]). IV, The tumor cells have
lost the expression of HLA-A2 and
-B51. Open histograms represent
an irrelevant HLA control mu-
mAb (GAPA3 against HLA-A3).
(B) Immunohistochemical detec-
tion of HLA-A and -B antigens
and epithelial cells on consecutive
tissue sections of the correspond-
ing frozen tumor with the same
mAbs as used in A. Leukocytes
were stained with an mAb against
LCA, as described in Materials and
Methods. (C) MS analysis for
marker D6S265 on DNA isolates
from the flow-sorted vimentin-
and keratin-positive cell popula-
tions of the tumor cell suspen-
sion, and separate autologous
PBLs. The allelic ratios (p1/p2)
for PBLs and vimentin-positive
(vim1) are 1.4 and 1.5, respec-
tively. The arrow indicates com-
plete LOH at the second allele
(p2) in the epithelial (ker1) tu-
mor cell fraction. sm1, external
size marker of 104 bp; sm2, ex-
ternal size marker of 144 bp.968 The Genetic Basis of HLA Class I Loss in Cervical Cancer
A. Second, loss of an HLA-A/B haplotype, in conjunction
with LOH at 6p for at least 3 markers, was initially identi-
fied in 14 tumors (47%; Fig. 4 B). Examples from this cat-
egory are shown in Fig. 1 B, Fig. 2, and Fig. 3 B. In three
of the tumors in this category (tumors 4, 15, and 30), an
additional (third) HLA-A or -B allele was lost. In two
other tumors (49 and 17) in this category, all four HLA-A
and -B alleles were lost. In tumor 17, HLA class I antigens,
as measured by W6/32 mAb, were still expressed, but in
tumor 49, a proportion of tumor cells was unreactive with
the W6/32 mAb (Fig. 1 B). The question as to which
HLA-A and -B alleles belonged to which haplotype (hap-
lotype assignment) involved in LOH in these cases is ad-
dressed in the next section. Third, loss of expression of all
class I antigens, as detected by W6/32 mAb, with concur-
rent retention of 6p heterozygosity was observed in three
cases (10%; Fig. 4 C). A fourth case of total HLA class I an-
tigen loss was found in a fraction of tumor 49 (Fig. 1 B and
Fig. 4 B), as described above. In tumor 26, some HLA class
I antigen expression was detected on a small percentage of
diploid cells in the keratin-positive fraction (Fig. 1 C). For
one marker (TNF-a), the aneuploid tumor cell fractions of
tumor 34 did not show ROH, but an aberrant pattern of
LOH and additional alleles, similar to the tumor illustrated
in Fig. 5. Finally, in three tumors (10%), loss of all HLA-A
and -B allelic expression despite W6/32 reactivity, or
downregulation of B locus expression, together with allelic
retention and/or imbalance at 6p, was noticed (Fig. 4 D).
Four tumors (13%) expressed their constitutive HLA class
I phenotype, three of which showed complete retention at
6p (Fig. 4 E). The 6p LOH found in tumor 13 probably re-
flected loss of one of the HLA-A/B haplotypes for which
this patient was homozygous. In retrospect, this tumor was
therefore assigned to the second category (haplotype loss).
The resulting percentages of tumors assigned to both catego-
ries are carried through in Fig. 6 (see Discussion).
Tumor 57 did not fit any of the preceding categories (Fig.
4 F). At the phenotype level, this tumor had homogeneously
lost expression of HLA-A1 and -B8. However, this was not
concurrent with extended LOH at 6p, as shown for other
Figure 3. Examples of frequently observed pat-
terns of genetic alterations as determined by MS
analyses. (A) a.i. in tumor 14 (phenotype shown in
Fig. 1 A), (B) LOH in tumor 49 (phenotype
shown in Fig. 1 B), and (C) ROH in tumor 26
(phenotype shown in Fig. 1 C). Allelic ratio is cal-
culated for each marker by dividing the ratio of the
allelic peak heights (p1/p2) measured for the nor-
mal sample (PBL, vim1, or LCA1) by the ratio of
peak heights measured for tumor (Ker1) samples.
The inverse ratio is taken for values ,1. Complete
loss of one of the two alleles represents true LOH,
ratios #1.3 represent ROH. Ratios $1.8 repre-
sent a.i. sm, size marker; di, diploid; an, aneuploid.969 Koopman et al.
tumors with an HLA-A and -B (haplotype) loss (Fig. 4 B).
The MS analysis for this tumor demonstrated an alternate
pattern of MS instability (MSI), homozygosity, ROH,
“shifted LOH,” and again ROH for consecutive MS mark-
ers spanning the HLA class I gene region (Fig. 5).
MS Analysis and/or PCR-based Haplotype Assignments
In tumors 4, 15, 30, 49, and 17 (Fig. 4 B) it was not di-
rectly clear which HLA-A/-B haplotype was associated
with the observed LOH. In tumor 15, heterogeneity of
HLA-A24 expression was observed within the (HLA-
A74/-B62–negative) tumor cell fraction. Since an identical
LOH pattern (Fig. 4 B) was observed in both of the sepa-
rately flow-sorted HLA-A24–positive and –negative cell
fractions, this LOH was therefore assigned to the HLA-
A74/-B62 haplotype.
Tumors 4 and 30 were both heterozygous for the HLA-
Bw4/Bw6 “broad” specificities. To determine which of the
two HLA-B alleles was implicated in the genomic loss at
6p21.3, a Bw4- and Bw6-specific PCR was performed on
the normal and tumor cells. In tumor 4, HLA-Bw4 (HLA-
B44) sequences were amplified in the tumor and normal
DNA, whereas the Bw6-specific PCR was negative in the
tumor DNA only (data not shown). Therefore, the observed
LOH at 6p in this tumor included the HLA-A2 and -B8
haplotype. Similarly, in tumor 30, HLA-Bw6 (HLA-B7) se-
quences were amplified in the tumor and normal DNA,
whereas the Bw4-specific PCR was negative in the tumor
DNA only (data not shown). Thus, the HLA-A33 and -B44
alleles were implicated in the haplotype LOH.
As discussed earlier, the LOH in tumor 49 involved the
HLA-A26/-B51 haplotype (Fig. 1 B and Fig. 3 B). For tu-
Figure 4. HLA-A/B phenotypes and chro-
mosome 6p MS genotype in 30 cervical cancer
cell suspensions. The relative position on chro-
mosome 6 of each MS marker in relation to
HLA-A, -B, and -C genes is shown at the top.
Boxes represent downregulated alleles on tu-
mor cells (by definition concurrently expressed
on internal control cells). Alleles belonging to
the same haplotype are underlined. an, aneu-
ploid; di, diploid; 1, positive expression of the
boxed allele(s); 2, no expression of the boxed
allele(s); 1/2, heterogeneous (i.e., positive and
negative) expression of the boxed allele(s).
LOH/D, the second allele is shifted to the left
(shortened) in tumor cell fraction compared
with the normal allelic pattern in PBLs. Allelic
ratios were calculated and interpreted as de-
scribed in the legend to Fig. 3. White, ROH
(ratios # 1.3); gray, a.i. (ratios $1.8 with values
shown). Values in between ROH and a.i. are
shown. Black, LOH (no value shown in cases
of complete LOH, or ratios $4 with values
shown). Of the cases analyzed for mutations (*),
those in which mutations were actually defined
(see Table II) are indicated (**).970 The Genetic Basis of HLA Class I Loss in Cervical Cancer
mor 17, which was homozygous for HLA-Bw4, the Bw4/
Bw6 PCR was not relevant for assigning the haplotype af-
fected by LOH. Since all alleles were lost in this particular
case, elucidation of the haplotype implicated in LOH has
been abandoned.
Tumors 46 and 47 were initially assigned to the first cat-
egory (allelic loss), since at the phenotypic level, only one
HLA-B allele was downregulated. However, the extensive
LOH observed across 6p for all informative MS markers
prompted further inquiry into suspected loss of an HLA-A
and -B haplotype by LOH in both cases. Since both tu-
mors were of the HLA-A2, -A11 type, different PCRs for
these alleles were performed on normal and tumor DNA
from these tumor cell suspensions. In fractions of both tu-
mors 46 and 47, the HLA-A11–specific PCR was negative
and the HLA-A2–specific PCR was positive, whereas
both HLA-A–specific PCRs were positive on DNA from
the corresponding normal cells (data not shown). Based on
these results, both cases were assigned to the haplotype
LOH loss category, leaving the observed HLA-A11 ex-
pression as unexplained “rest expression.”
Mutation Analyses
To analyze whether mutations in HLA class I genes had
caused allelic loss (tumors 6, 14, 24, 50, and 58 in Fig. 4
A), third allele loss (tumors 4, 15, and 30 in Fig. 4 B), or
whether mutations in b2m genes had caused loss of total
HLA class I antigen expression as defined by the lack of
W6/32 reactivity (tumor 49 in Fig. 4 B, tumors 26, 34,
and 59 in Fig. 4 C), the relevant cases were analyzed for
the presence of mutations. The detected mutations are
shown in Table II.
Sequencing. PCR amplimers of HLA-A or -B exons 2–4
or b2m exon 1–2 from tumor and normal DNA were se-
quenced. In the allelic loss category, tumor 6 was found to
contain a C to T substitution at codon 180 in exon 3 of
the HLA-A2 gene, generating a stop codon (Table II). In
tumor no. 14, a deletion of z230 nucleotides containing
parts of intron 2 and exon 3, was found in the HLA-B63
(B15) gene. In DNA from tumor 58, the HLA-A24 sequence
was not detected in any of the screened exons. This ap-
pears to be caused by partial loss of chromosome 6p het-
erozygosity observed in tumor 58 (Fig. 4 A). For tumors
24 and 50 in this category, the tumor and wild-type se-
quences in the screened HLA-A or -B exon 2–4 products
were identical. For tumor 24, the exon 3 amplimer was
not available, because of the lack of material.
In the “haplotype LOH 1 1 allele” category, a 16-nucleo-
tide deletion and insertion of a G were found at codon 121
in the HLA-B7 exon 3 sequence of tumor 30. The HLA-
A24 mutations in tumor 15 of this category are described
under PCR-based mutation detection below. In tumor 4,
the HLA-B44 sequences detected in the exon 2–4 am-
plimers were all wild-type.
In the “total class I loss” category (Fig. 4 C), no b2m mu-
tations were detected in the exon 1 and 2 sequences ana-
lyzed. However, in tumor 49 in the “haplotype LOH 1 2
allele” category, which contained a fraction of cells that did
not react with W6/32, a two-nucleotide deletion was found
in exon 1 of the b2m gene (Table II). This deletion would
result in frameshift, as observed in the tumor DNA, leading
to a completely altered amino acid translation.
PCR-based Mutation Detection. The loss of HLA-A24
sequences in tumor 58 was independently confirmed by
allele-specific PCR using the HLA-A24–specific primers
described in Table I and the Materials and Methods. A
375-bp HLA-A24–specific product, as observed in DNA
from PBLs from the same patient, was not detected in tu-
mor-derived DNA. Tumor cell suspension 15 (in the
“haplotype LOH 1 1 allele” category) corresponded to a
cell line and primary tumor previously reported to contain
point mutations in the HLA-A24 gene at codons 89 and
279 of exon 2 and 5, respectively, both resulting in stop
codons (20). Therefore, we confirmed these indepen-
dently by PCR amplification using primers specific for the
mutation and wild-type sequences as described (20). Both
mutations were detected in DNA from HLA-A24–nega-
tive fraction of the tumor cell suspension, whereas DNA
from the HLA-A24–positive fraction was amplified only
in the wild-type–specific reaction (data not shown).
Discussion
This study demonstrates a high frequency of HLA class I
alterations in cervical cancer, characterized by extensive
pheno- and genotypical inter- and intratumor heterogene-
ity. In contrast with previous studies of cervical and other
cancers (4–6), the multiparameter DNA flow cytometry
approach presented in this paper enabled us to concurrently
analyze HLA class I pheno- and genotype alterations di-
rectly in fresh cervical tumor cell suspensions. A major ad-
Figure 5. Unclassified pattern of genetic alterations in tumor 57, as deter-
mined by MS analysis. Results for corresponding PBLs and flow-sorted kera-
tin-positive (ker1) tumor cell fraction are shown (see Fig. 3 legend). Marker
positions on chromosome 6 are depicted in Fig. 4. m.s.i., MSI; LOH/D, the
second allele is shifted to the left (shortened) in tumor cell fraction compared
with the normal allelic pattern in PBL. sm1, external size marker.971 Koopman et al.
vantage of the present method of tumor cell separation
from its tissue context is the possibility for detailed molecu-
lar genetic analyses of distinct cell populations in tumors
that display phenotypic intratumor heterogeneity, as well as
to avoid contamination by normal cell infiltration.
We showed that among the 90% of the cervical cancers
with altered HLA class I phenotypes, almost 70% were
caused by multiple genetic alterations at chromosome 6p
(Fig. 4, Fig. 6, and Table II). Loss of at least one HLA hap-
lotype was caused by tumor-specific LOH at chromosome
6p in 50% of the cases. In one third of these cases, addi-
tional allelic losses were demonstrated, most of which were
proven to be due to mutations in HLA class I or b2m
genes. Moreover, in more than half of the single allelic loss
cases HLA class I gene mutations were found. The loss
phenotypes observed in the remaining tumors included
HLA-A/B or HLA-B locus loss, and total HLA class I loss.
Thus far, some of the observed HLA class I phenotypes
and associated genotypes have been separately described,
primarily in cell lines of a few different tumor types. HLA
haplotype losses caused by LOH at chromosome 6p have
been demonstrated in cell lines from melanoma, colon,
pancreas, and laryngeal and cervical cancers (8, 10, 11, 19,
34), few of which were confirmed in the corresponding
primary cancers. These data prove that LOH at chromo-
some 6p21.3, which occurs at high frequencies in cervical
cancer (25–28, 35, 36), indeed represents an important and
common mechanism by which HLA genes and their prod-
ucts are abolished.
In five of the eight cases with (additional) allelic loss,
mutations were demonstrated, varying from point muta-
tions to larger deletions in the relevant HLA-A or -B genes
(Table II). In a previous report, we described a four-nucle-
otide insertion in exon 2 of the HLA-B15 gene leading to
loss of HLA-B15 expression in a cervical cancer cell line
and its primary tumor (20). Mutations underlying allelic
loss have also been characterized in a few melanoma cell
lines (12, 13, 15) and a colon cancer cell line (10). These
vary from a point mutation in intron 2 (15), partial deletion
of the 59 end of the HLA class I gene (13), to partial chro-
mosomal deletions or rearrangements (10, 12). However,
the presence of these defects in the original tissues was not
investigated in these studies.
Because little information was available on mutations in
HLA class I genes in tumors, we initially chose to screen for
mutations in those HLA class I regions that seemed prone for
(germline) mutations in individuals with HLA “null” or
“blank” alleles (37–39). These are the exons 2, 3, and 4, en-
Table II. Observed Sequence Alterations* Associated with Loss of Expression of HLA Class I (Alleles)
Tumor Sequence Observed at position (nt/codon)‡ Type of mutation
6 HLA-A2 Wt: CAG
Mt: TAG
Exon 3 (nt 610/codon 180) Single base substitution
® stop codon
14 HLA-B63 From intron 2 (nt 141 or 146)
to exon 3 (nt 485 or 490/
codon 138 or 140)
230-nt deletion
58 HLA-A24 Not detected in tumor sample Exons 2–4 Partial chromosome loss§
15 HLA-A24i Wt: GAG
Mt: TAG Exon 2 (nt 337/codon 89) Single base substitution
® stop codon
Wt: CAG
Mt: TAG Exon 5 (nt 907/codon 279) Single base substitution
® stop codon
30 HLA-B7 Wt: GGC AAG GAT TAC ATC GCC CTG AAC GAG GAC
Mt: GGC A--------------------GG AAC GAG GAC Exon 3 (nt 434–449/
codons 121–126)
16-nt deletion and
insertion of a G
49 b2m Wt: TCT CTT TCT GGC CTG Exon 1
Mt: TCT TTC TGG CCT G
 (nt 924–925 [TC: underlined]
or 925–926 [CT: bold])
2-nt deletion
® frameshift
*Genomic regions screened on normal and tumor DNA for HLA-A and HLA-B were exons 2–4; those for b2m were exons 1 and 2.
‡Nucleotide (nt) positions in exons were counted starting from the first nucleotide in exon 1, excluding introns (cDNA sequence). Intron sequences
were described by Cereb et al. (reference 58). b2m sequence data are available from EMBL/GenBank/DDBJ under accession nos. M17986 and
M17987.
§MS analysis results (see Fig. 4 A) for this tumor indicate inclusion of the HLA-A24 gene in partical chromosomal loss in the HLA region. In addi-
tion, HLA-A24–specific PCR was negative on tumor DNA (see text).
iMutations were originally described in a cell line derived from this tumor (reference 19), and were confirmed in the tumor cell population used in
the present study by PCR (see text).972 The Genetic Basis of HLA Class I Loss in Cervical Cancer
coding the extracellular a1, a2, and a3 domains, respec-
tively. The upstream regulatory regions, exons 1 (leader pep-
tide) and 5 (transmembrane domain), and the introns of the
relevant HLA class I genes were not analyzed, but it is now
increasingly clear that these may harbor mutations that lead
to downregulation or loss of cell surface expression (15, 20).
This was also substantiated by the involvement of intron 2 in
a mutation identified in the present study (Table II). Further
investigations are in progress to clarify the mechanisms un-
derlying the as yet unexplained allelic losses.
One of four cases of total HLA class I antigen downreg-
ulation, as measured by complete lack of W6/32 reactivity,
was explained by a combination of haplotype loss by LOH
at 6p and mutation in exon 1 of the b2m gene. We re-
stricted our screening of b2m mutations to exons 1 and 2,
in which mutations underlying total HLA class I antigen
loss were previously identified in melanoma and colon can-
cer cell lines and primary tumors (14, 17, 18, 40–43). Yet,
mutations may also occur in sequences outside the regions
screened (42, 43), which is the subject of further studies.
The high frequency of phenotype alterations established
in our study exceeds the variable estimations previously
made, ranging from z30 to 80% (4, 22, 44–46). This vari-
ation was probably mostly due to the lack of complete al-
lele coverage by the panels of antibodies used. We detected
all HLA-A and -B alleles represented in the patient popula-
tion through the use of an extensive panel of HLA-directed
mAbs, which allowed for classification of the 30 tumors
into distinct HLA loss phenotypes. By demonstrating ex-
tensive LOH at 6p underlying haplotype loss in 15 cases (3
that harbor additional mutations in b2m or HLA class I
genes) and allele-specific mutation in 3 cases, we have
proven a genetic basis for 67% of the observed altered HLA
class I phenotypes. As the yet unsolved cases in the haplo-
type and/or allelic loss categories as well as the total HLA
class I antigen losses may harbor mutations outside the re-
gions screened, this extent may be even higher.
The remaining tumors with altered phenotypes include
two cases of HLA-B locus–specific downregulation and one
case of HLA-A/B loss with retention of W6/32 reactivity.
Further investigations are needed to elucidate the basis for
these losses. HLA-B locus–specific downregulation has also
been observed in a cervical cancer cell line and melanoma
cell lines and is thought to be caused by defects at the tran-
scriptional level (16, 19, 47). Reduced expression of trans-
porter associated with antigen processing (TAP)-1/2 at the
protein or RNA level has been described as a mechanism
underlying reduced or total loss of HLA class I antigen ex-
pression in several tumors (48). In our series, the possibility
of disturbed TAP function remains to be explored.
Heterogeneity, with regard to HLA class I antigen ex-
pression and DNA content, was often observed within in-
dividual tumors, and offers an outstanding opportunity to
study HLA class I antigen losses during tumor progression,
as reflected by aneuploidization. Taking into consideration
that aneuploid tumor cells are preceded by diploid precur-
sor cells, the observation of HLA losses in diploid cell frac-
tions of largely aneuploid tumors (Fig. 4, tumors 6, 10, 25,
36, and 56) in this study suggests that loss of HLA class I
antigens occurs early during tumor development. Tumors
10, 25, and 36 in the haplotype loss category (Fig. 4 B)
show LOH and haplotype loss in such diploid cells. Simi-
larly, in the allelic loss category, the HLA-A2 loss in tumor
6 is already present in the diploid cells (Fig. 4 A), suggesting
that the mutation underlying this loss (Table II) may have
occurred early during tumor progression, at least before
manifestation of the largely aneuploid tumor population.
On the other hand, HLA class I antigen loss was also found
in conjunction with (tumors 12, 14, 23, and 26), or after
(tumors 15, 28, 34, 49, and 50) aneuploidization (Fig. 4).
These observations were not confined to any particular
HLA loss category. Thus, HLA class I antigen loss seems
independent of increased genomic instability, as reflected
by aneuploidy.
Figure 6. Frequency distribution of HLA
loss phenotypes and 6p21.3 MS genotypes
in 30 cervical cancer cell suspensions. Sche-
matic representation of the results presented
in Fig. 4. Altered HLA-A/B phenotypes
were found in 90% of the tumors. Relative
frequencies of specific HLA loss phenotypes
are depicted with the associated MS results.
In 50% of the tumors, at least one haplotype
is lost by LOH. Further proposed loss
mechanisms are presented in italics. In the
“haplotype 1 1 allele” loss category, class I
gene mutations underlying loss of the addi-
tional allele were proven in two (tumors 15
and 30) of the three cases. In the “1 allele”
loss category, a class I gene mutation was
demonstrated in three (tumors 6, 14, and
58) of the five cases. A b2m mutation was
found underlying loss of the additional HLA
class I alleles in one (tumor 49) of the two
cases in the “haplotype 1 2 alleles” loss category. However, in the “total class I (w6/32-)” loss category, no mutations were detected in exons 1–2 of the
b2m gene. The mechanisms underlying the “HLA-B locus” and “HLA-A/B (w6/321)” loss categories may be of a regulatory nature. One case (tumor
57) of haplotype loss is in the unclassified loss (“?”) category (see Fig. 5 and text).973 Koopman et al.
The exact onset of HLA class I antigen loss in the course of
cervical carcinogenesis is not clear. Loss of class I antigen ex-
pression has previously been indicated in premalignant cervi-
cal intraepithelial neoplasia lesions (23, 49), without investiga-
tion of the underlying mechanisms. Conversely, LOH at 6p
has been demonstrated in cervical intraepithelial neoplasia le-
sions (20, 50, 51) with concomitant loss of HLA-A/B haplo-
type expression demonstrated in one report (20). Ongoing
analyses of LOH patterns and/or mutations in the premalig-
nant and/or metastatic lesions of the tumors studied here may
provide information regarding the time of occurrence of the
genetic changes underlying HLA class I antigen loss.
Our data did not point to a relation between HPV types
and specific loss mechanisms. It remains unknown whether
the pheno- and genotypical changes in HLA class I are re-
lated to the presence of HPV and/or HPV type. If HPV
drives the cell to lose presentation capacity by HLA class I
antigen loss, then a difference could exist between HPV-
induced and non-HPV–related tumors. As virtually all cer-
vical cancers contain HPV DNA, this cannot be assessed
within this tumor type. Similar HLA changes have been
identified in non-HPV–related tumors such as melanoma
and colon. It would be interesting to compare the occur-
rence and predominance of the various different pheno-
types and their underlying mechanisms among different
tumors. However, a complete inventory of HLA loss phe-
notypes and underlying mechanisms in other primary tu-
mors, comparable to the one presented here, is needed be-
fore any further conclusions can be drawn.
The multiplicity of molecular mechanisms leading to al-
tered HLA expression and phenotypic heterogeneity within
a given tumor is suggestive of selection of immunologically
privileged variants during its multistep evolution (2). We
previously showed in HLA-A24–positive and –negative
variant cell lines derived from the heterogeneous tumor 15,
that HLA-A24 expression was crucial for recognition by
CTLs present within the autologous bulk tumor-infiltrat-
ing leukocyte culture (20). Intratumor heterogeneity prob-
ably constitutes a major hurdle for effective immune sur-
veillance by T and/or NK cells. The limited success of
clinical immunotherapeutic efforts made so far against immu-
nogenic tumors such as melanoma and cervical cancer may
be partly explained by varied expression of tumor antigens
and the immunoselection that occurs after immunization
(52–55). Certainly, the HLA class I tumor phenotype re-
mains a very important parameter in relation to the antici-
pated patient-specific immune responses in any future in-
vestigation of natural immune responses or T cell–based
immunotherapy in cervical or other types of cancer.
We conclude that the loss of HLA class I antigen expres-
sion in cervical cancer is widespread, heterogeneous, and
predominantly results from irreversible genetic changes at
chromosome 6p21.3, which may seriously affect natural
immunity and/or therapeutic immune intervention.
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